Get the Stockscreener App
73.77
0.20%
0.15
After Hours:
73.77
Cytokinetics Inc stock is traded at $73.77, with a volume of 1.72M.
It is up +0.20% in the last 24 hours and down -3.51% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$73.62
Open:
$74.66
24h Volume:
1.72M
Relative Volume:
0.85
Market Cap:
$10.26B
Revenue:
$105.82M
Net Income/Loss:
$-829.61M
P/E Ratio:
-10.78
EPS:
-6.8429
Net Cash Flow:
$-548.92M
1W Performance:
+1.44%
1M Performance:
-3.51%
6M Performance:
+15.94%
1Y Performance:
+38.35%
1-Day Range:
$73.50
$75.98
1-Week Range:
$72.39
$76.81
52-Week Range:
$47.22
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
73.77 | 10.26B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Wells Fargo | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-18-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics Inc (CYTK) Director Robert Landry Sells 1,000 Shares - GuruFocus
Cytokinetics director Robert Landry sells $74,660 in shares By Investing.com - Investing.com South Africa
Cytokinetics director Robert Landry sells $74,660 in shares - Investing.com
Cytokinetics (NASDAQ: CYTK) director plans 2,000-share Rule 144 sale - Stock Titan
If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Cantor Fitzgerald reiterates Overweight on Cytokinetics stock By Investing.com - Investing.com Australia
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says - marketscreener.com
Cytokinetics at citigroup summit: hcm expansion drives growth hopes By Investing.com - Investing.com Nigeria
Transcript : Cytokinetics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03 - marketscreener.com
Cytokinetics at citigroup summit: hcm expansion drives growth hopes - investing.com
Cytokinetics (CYTK) Insider Sell: EVP Research & Development Fad - GuruFocus
Could Aficamten Give Cytokinetics the First Approved nHCM Treatment? - Yahoo Finance
Cytokinetics, Inc. (CYTK) Stock Analysis: Biotech Growth With 51% Upside Potential - DirectorsTalk Interviews
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? - Zacks Investment Research
Cytokinetics to Participate in September Investor Conferences - marketscreener.com
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects? - Eastern Progress
Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $357,400, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (NASDAQ: CYTK) director sale under 10b5-1 plan - Stock Titan
Cytokinetics (NASDAQ: CYTK) director moves to sell 5,000 vested shares - Stock Titan
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $112 - Moomoo
Cytokinetics (CYTK) Presents New Phase 3 Data, Is It Still 34% Undervalued? - Yahoo Finance
Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential - Investing.com
Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential By Investing.com - Investing.com Canada
Cytokinetics (CYTK) Reaches A Phase 3 First In Non Obstructive HCM - Yahoo Finance
CYTK5615147 Bond Profile — Key Metrics - TradingView
Cytokinetics (CYTK) CEO exercises options, sells 7,500 shares - Stock Titan
What's Going On With Cytokinetics Stock Today?Cytokinetics (NASDAQ:CYTK) - Benzinga
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy - BioPharma Dive
Cytokinetics, Inc. (CYTK) Stock Analysis: A Biotech Powerhouse with 52.45% Upside Potential - DirectorsTalk Interviews
Cytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCMHas The Bull Case Changed? - webull.com
Cytokinetics Announces Additional ACACIA-HCM and MAPLE-HCM Results Showing Aficamten Benefits Across Hypertrophic Cardiomyopathy Spectrum - Quiver Quantitative
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
ESC: Cytokinetics Confirms Strong Case For Myqorzo Label Expansion - insights.citeline.com
If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Why Cytokinetics (CYTK) Stock Is Down Today - Quiver Quantitative
Cytokinetics details trial win for what could be its next approval - STAT
Cytokinetics Announces Positive Phase 3 ACACIA-HCM Results for Aficamten in Non-Obstructive Hypertrophic Cardiomyopathy - Quiver Quantitative
Cytokinetics' aficamten showed gains in patient scores and exercise in Phase 3 trial - Stock Titan
Cytokinetics (CYTK) Institutional Ownership 2026 $CYTK - MarketBeat
News on AstraZeneca, Cytokinetics, Novartis and more — what to look out for at ESC 2026 - Endpoints News
Cytokinetics, Incorporated (CYTK) Stock Analysis: Evaluating a Potential 43% Upside in the Biotech Sector - DirectorsTalk Interviews
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 - Yahoo Finance
Cytokinetics succeeds where Bristol Myers failed in heart muscle disease - Endpoints News
Cytokinetics to Present ACACIA-HCM Hot Line Results and Host Investor Event at ESC Congress 2026 - Quiver Quantitative
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) ... - Caledonian Record
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock? - Eastern Progress
Cytokinetics (CYTK) EVP Research & Development Fady Malik Sells 3,500 Shares - GuruFocus
Cytokinetics EVP Fady Ibraham Exercises Stock Options and Sells 3,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):